Cohance Lifesciences Limited (COHANCE)

Current Price: ₹0.00

Back to Home
Stock Performance

Quarterly Financials

Consolidated Standalone
Particulars Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 402.02 549.31 1,104.88 544.55 619.12
YOY Revenue Growth % - - - - 54%
Other Income 10.57 14.17 29.77 6.16 -1.84
Total Income 412.59 563.48 1,134.65 550.71 617.28
Total Expenses + 360.99 492.62 980.02 505.25 580.86
Cost of Materials Consumed 70.24 178.33 369.93 196.50 138.96
Employee Benefit Expense 89.08 133.32 260.04 118.68 128.99
Other Expenses 105.38 155.84 322.61 171.61 177.00
Operating Profit 41.03 56.69 124.86 39.30 38.26
OPM % 10.2% 10.3% 11.3% 7.2% 6.2%
Profit Before Tax + 51.60 62.76 146.53 40.60 19.91
Tax Expense 12.87 16.36 33.74 11.58 11.60
Tax % 24.9% 26.1% 23% 28.5% 58.3%
Profit After Tax 38.73 46.40 112.79 29.02 8.31
EPS (Basic) 1.65 1.28 3.22 0.96 0.51

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2025
Revenue from Operations 1,197.58
YOY Revenue Growth % -
Other Income 58.56
Total Income 1,256.14
Total Expenses + 912.22
Cost of Materials Consumed 222.66
Employee Benefit Expense 249.56
Other Expenses 267.53
Operating Profit 285.36
OPM % 23.8%
Profit Before Exceptional 343.92
Exceptional Items 0.00
Profit Before Tax + 343.92
Tax Expense 79.15
Tax % 23%
Profit After Tax 264.77
EPS (Basic) 10.52

Balance Sheet

Particulars Mar 2025
ASSETS
Non-Current Assets + 2,143.16
Property, Plant & Equipment 995.20
Capital Work in Progress 254.83
Non-Current Investments 144.95
Goodwill 655.11
Other Intangible Assets 63.11
Current Assets + 853.28
Inventories 166.57
Trade Receivables 284.44
Cash and Cash Equivalents 85.40
Current Investments 191.74
LIABILITIES & EQUITY
Total Equity 0.00
Equity Share Capital 25.46
Other Equity 1,671.12
Non-Current Liabilities 825.92
Current Liabilities 365.19
Total Liabilities 1,191.11

Cash Flow Statement

Particulars Mar 2025
Cash from Operating Activities 288.16
Cash from Investing Activities -255.30
Cash from Financing Activities 3.32
Net Increase/Decrease in Cash 38.17